ATLANTA, GA — August 18, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX) will present at the Emerging Growth Conference on Wednesday, August 20, 2025. Chairman and CEO David Dodd will discuss GeoVax’s GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine, from 3:40 PM to 3:50 PM Eastern Time.
The company recently received favorable Scientific Advice (SA) from the European Medicines Agency (EMA), potentially accelerating the regulatory approval timeline for GEO-MVA. GeoVax will also highlight its MVA platform and U.S.-based continuous cell line manufacturing, positioning it to address gaps in vaccine supply, pandemic readiness, and biosecurity.
Participants can register for the conference at https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=govx and submit questions in advance to Questions@EmergingGrowth.com or during the presentation. A replay will be available on www.EmergingGrowth.com and YouTube.com/EmergingGrowthConference.
GeoVax Labs, Inc. develops vaccines against infectious diseases and therapies for solid tumor cancers. Its lead program, GEO-CM04S1, is a next-generation COVID-19 vaccine in Phase 2 trials. The oncology program, Gedeptin®, recently completed a Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax anticipates progressing its Mpox and smallpox vaccine directly to a Phase 3 clinical evaluation.
Contact: info@geovax.com, 678-384-7220. Media Contact: Jessica Starman, media@geovax.com
Source: GeoVax
